Published on
May 5, 2020
- 20:01 GMT
Zogenix Provides Corporate Update and Reports First Quarter 2020 Financial Results
FDA PDUFA target action date of June 25, 2020, for FINTEPLA® NDA in Dravet syndrome Plan to meet with FDA in second half of 2020 to discuss planned FINTEPLA Lennox-Gastaut syndrome sNDA Closed public offering of common stock for net proceeds of $221.7 …
Distribution channels:
Business & Economy, Healthcare & Pharmaceuticals Industry
...
